


Cumberland Pharmaceuticals Inc. (CPIX)

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001087294

Cumberland Pharmaceuticals Inc. CPIX; healthcare	
Grade	D A B C D E fourth fifth of 371 graded peers percentile 71.6; sampling error 2.5 points; lower is stronger
Rank	266 of 371
Profitability	C percentile 42.9
Solvency	C/D percentile 58.2
Growth and financing	D percentile 66.7
Reliability	0.83 AUC filers with \$12.5M to \$120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$12.5M to \$120M assets total assets \$76.8M
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active not computable: distress, fortress balance sheet
Inputs computable	10 of 14
Graded from	filings received through Mar 9, 2026 214 days before the rescans; latest periodic filing 10-Q received Aug 7, 2026
Last close	\$7.07 2026-10-08; market equity \$105.9M
Price used in grade	None



D, the sloth

fourth fifth of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescans

split-adjusted close; the letter is fixed at the rescans that set it



Rescans on file: A/B from Nov 21, 2023, B from Feb 21, 2024, C from Mar 21, 2024, D from Mar 21, 2024

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Mar 9, 2026

Cumberland Pharmaceuticals Inc. ("Cumberland," the "Company," or as used in the context of "we," "us" or "our"), is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription pharmaceuticals. We are dedicated to our mission of working together to provide unique products that improve the quality of patient care. Our primary target markets are hospital acute care, gastroenterology and oncology. These medical specialties are characterized by relatively

concentrated prescriber bases that we believe can be served effectively by relatively small, targeted sales forces.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 42.9						
Gross profitability		49.3%	32.2%	23.7	372	2025-12-31
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(10.2%)	(6.6%)	40.9	811	2025-12-31
Gross margin stability, five years		3.9 pts	2.8 pts	64.0	243	2025-12-31
Solvency, sleeve percentile 58.2						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		(0.86)	(0.31)	40.4	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		(5.63x)	(4.51x)	45.0	81	2025-12-31
Current ratio		1.01x	2.96x	89.3	839	2025-12-31
Growth and financing, sleeve percentile 66.7						
Revenue growth, three-year compound		2.0%	10.0%	66.7	415	2025-12-31
Free cash flow growth, three-year compound		(16.7%)	10.9%	88.4	96	2025-12-31
Reinvestment rate		not computable	37.1%			pretax income must exceed the validity floor and imply a 0%-100% tax rate
Asset growth, three years		(6.1%)	2.1%	63.7	704	2025-12-31
Net share issuance, one year		7.1%	2.5%	47.9	634	2026-03-04

Among 371 peers

healthcare; letters are fifths of this list



Rank	Company	Percentile	Letter	Warnings
261	Bioventus Inc. (BVS)	70.3	D	

262	Ovid Therapeutics Inc. (OVID)	70.5	D	dilution, short runway
263	uniQure N.V. (QURE)	70.8	D	fortress balance sheet
264	Regeneron Pharmaceuticals, Inc. (REGN)	71.1	D	
265	AbCellera Biologics Inc. (ABCL)	71.4	D	
266	Cumberland Pharmaceuticals Inc. (CPIX) <	71.6	D	
267	Bausch & Lomb Corp. (BLCO)	71.9	D	
268	Pennant Group, Inc. (PNTG)	72.2	D	
269	Bausch Health Companies Inc. (BHC)	72.4	D	
270	3M Co. (MMM)	72.7	D	
271	Elanco Animal Health Inc. (ELAN)	73.0	D	

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	171.7%	8.0%	94
Distance from 52-week high	(22.2%)	(31.4%)	62
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	4.6%	(1.0%)	79
Book value to price	0.17	0.28	36
Sales to price	0.43	0.31	61
Composite equity issuance, five years	(23.3%)	20.3%	6
Relative strength against the sector, log excess return	0.79	(0.14)	94

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$3.9M
Operating cash flow, four quarters	\$745,969
Months of runway	not finite
Days since last periodic filing	63 (10-Q received Aug 7, 2026)
Median daily dollar volume, 63 sessions	\$508,656

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$44.5M	2025-12-31	2026-03-09	10-K	0001087294-26-000020
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$6.7M	2025-12-31	2026-03-09	10-K	0001087294-26-000020
3	assets	us-gaap:Assets	\$76.8M	2025-12-31	2026-03-09	10-K	0001087294-26-000020
4	net income	us-gaap:NetIncomeLoss	-\$2.8M	2025-12-31	2026-03-09	10-K	0001087294-26-000020
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$4.9M	2025-12-31	2026-03-09	10-K	0001087294-26-000020
6	assets	us-gaap:Assets	\$75.6M	2024-12-31	2026-03-09	10-K	0001087294-26-000020
7	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$37.9M	2024-12-31	2026-03-09	10-K	0001087294-26-000020
8	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$6.6M	2024-12-31	2026-03-09	10-K	0001087294-26-000020
9	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$39.6M	2023-12-31	2025-03-07	10-K	0001628280-25-011366

10	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$6.1M	2023-12-31	2025-03-07	10-K	0001628280-25-011366
11	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$42.0M	2022-12-31	2024-03-13	10-K	0001628280-24-010725
12	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$9.1M	2022-12-31	2024-03-13	10-K	0001628280-24-010725
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$35.0M	2021-12-31	2023-03-13	10-K	0001628280-23-007727
14	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$8.8M	2021-12-31	2023-03-13	10-K	0001628280-23-007727
15	current assets	us-gaap:AssetsCurrent	\$37.1M	2025-12-31	2026-03-09	10-K	0001087294-26-000020
16	current liabilities	us-gaap:LiabilitiesCurrent	\$36.7M	2025-12-31	2026-03-09	10-K	0001087294-26-000020
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$26.8M	2025-12-31	2026-03-09	10-K	0001087294-26-000020
18	operating income	us-gaap:OperatingIncomeLoss	-\$2.8M	2025-12-31	2026-03-09	10-K	0001087294-26-000020
19	book equity	us-gaap:StockholdersEquity	\$24.9M	2025-12-31	2026-03-09	10-K	0001087294-26-000020
20	liabilities	us-gaap:Liabilities	\$52.3M	2025-12-31	2026-03-09	10-K	0001087294-26-000020
21	interest expense	us-gaap:InterestExpense	\$495,990	2025-12-31	2026-03-09	10-K	0001087294-26-000020
22	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$97,903	2025-12-31	2026-03-09	10-K	0001087294-26-000020
23	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$612,186	2024-12-31	2026-03-09	10-K	0001087294-26-000020
24	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$66,461	2024-12-31	2026-03-09	10-K	0001087294-26-000020
25	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$6.1M	2023-12-31	2025-03-07	10-K	0001628280-25-011366
26	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$281,268	2023-12-31	2025-03-07	10-K	0001628280-25-011366
27	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$8.5M	2022-12-31	2024-03-13	10-K	0001628280-24-010725
28	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$102,148	2022-12-31	2024-03-13	10-K	0001628280-24-010725
29	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$4.1M	2025-12-31	2026-03-09	10-K	0001087294-26-000020
30	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	\$2.8M	2025-12-31	2026-03-09	10-K	0001087294-26-000020
31	income tax	us-gaap:IncomeTaxExpenseBenefit	\$40,256	2025-12-31	2026-03-09	10-K	0001087294-26-000020
32	current assets	us-gaap:AssetsCurrent	\$36.5M	2024-12-31	2026-03-09	10-K	0001087294-26-000020
33	current liabilities	us-gaap:LiabilitiesCurrent	\$31.6M	2024-12-31	2026-03-09	10-K	0001087294-26-000020
34	assets	us-gaap:Assets	\$81.8M	2023-12-31	2025-03-07	10-K	0001628280-25-011366
35	assets	us-gaap:Assets	\$92.9M	2022-12-31	2024-03-13	10-K	0001628280-24-010725
36	shares outstanding	dei:EntityCommonStockSharesOutstanding	14,956,627	2026-03-04	2026-03-09	10-K	0001087294-26-000020
37	shares outstanding	dei:EntityCommonStockSharesOutstanding	13,968,394	2025-03-04	2025-03-07	10-K	0001628280-25-011366